,
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes, though some are now also licensed for weight management
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials
Mycotoxins have been shown to disrupt tight junction proteins, increase zonulin expression, and compromise intestinal barrier integrity 17
Genetic Predispositions in GLP-1 Pathways: How Personalization Supports Canadian Treatment Selection Emerging evidence suggests that genetic variants in GLP-1 receptor (GLP1R rs6923761) and glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437) pathways may influence individual responses to GLP-1 therapy
Scientists are exploring whether this therapy may help regulate inflammation and immune activity in the body, which could influence behavior, attention, or overall well-being